Literature DB >> 2017647

Chemoprophylaxis for bacterial infections: principles of and application to meningococcal infections.

B Schwartz1.   

Abstract

Chemoprophylaxis with antibiotics is both feasible and desirable for prevention of a potentially serious disease when specific groups at risk can be defined and when a safe, effective, and affordable prophylactic agent is available. Although the Advisory Committee on Immunization Practices recommends rifampin for prophylaxis of meningococcal disease, there are failures of treatment and adverse reactions associated with the administration of this drug, and it cannot be used during pregnancy. In 1987, during an outbreak of group A meningococcal disease in Saudi Arabia, the efficacy of a single intramuscular dose of ceftriaxone was compared with the standard regimen of rifampin for eradication of pharyngeal carriage of Neisseria meningitidis among persons at risk. Follow-up cultures indicated successful eradication for 97% of those who received ceftriaxone and 75% of those who received rifampin. Thus, although ceftriaxone exceeds rifampin in fulfilling the criteria for an effective prophylactic agent, recommendations regarding its use still must be made with caution because of limited clinical experience.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2017647     DOI: 10.1093/clinids/13.supplement_2.s170

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  Vaccination against meningococcus in complement-deficient individuals.

Authors:  B P Morgan; A Orren
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 4.  Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials.

Authors:  A Fraser; A Gafter-Gvili; M Paul; L Leibovici
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

Review 5.  Guidelines for control of meningococcal disease. Laboratory Centre for Disease Control. Canadian Consensus Conference on Meningococcal Disease.

Authors: 
Journal:  CMAJ       Date:  1994-06-01       Impact factor: 8.262

6.  Prophylactic antibiotic for prevention of posttraumatic meningitis after traumatic pneumocephalus: design and rationale of a placebo-controlled randomized multicenter trial [ISRCTN71132784].

Authors:  Behzad Eftekhar; Mohammad Ghodsi; Azar Hadadi; Mousa Taghipoor; Samira Zabihyan Sigarchi; Vafa Rahimi-Movaghar; Ehsan Sherafat Kazemzadeh; Babak Esmaeeli; Farideh Nejat; Alireza Yalda; Ebrahim Ketabchi
Journal:  Trials       Date:  2006-01-18       Impact factor: 2.279

Review 7.  Antibiotics for preventing meningococcal infections.

Authors:  Anca Zalmanovici Trestioreanu; Abigail Fraser; Anat Gafter-Gvili; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-25

8.  Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city.

Authors:  Hernando Pinzón-Redondo; Wilfrido Coronell-Rodriguez; Inés Díaz-Martinez; Angel Guzmán-Corena; Dagna Constenla; Nelson Alvis-Guzmán
Journal:  J Health Popul Nutr       Date:  2014-09       Impact factor: 2.000

Review 9.  Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness.

Authors:  John F Brundage
Journal:  Lancet Infect Dis       Date:  2006-05       Impact factor: 25.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.